Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
The Journal of Biological Chemistry|April 26, 2015
Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of "Humanized" Multiple Sclerosis-like DiseaseNathali Kaushansky, Miriam Eisenstein, Sigalit Boura-Halfon, et al.
Arthritis Research & Therapy|May 18, 2006
Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic miceAlexei von Delwig, Catharien M U Hilkens, Daniel M Altmann, et al.
Nature|November 10, 2021
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2Leo Swadling, Mariana O Diniz, Nathalie M Schmidt, et al.
Scientific Reports|September 27, 2022
Serum biomarkers associated with SARS-CoV-2 severityFabiani de Morais Batista, Marco Antonio Moreira Puga, Patricia Vieira da Silva, et al.
BMC Infectious Diseases|July 28, 2023
Multicenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations - a study protocol from the clinical and applied research in Chikungunya (REPLICK network)Giselle da Silva Duarte, Alexandra D Jones, Luciano Pamplona de Goes Cavalcanti, et al.
Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.
Science Immunology|December 28, 2020
Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infectionCatherine J Reynolds, Leo Swadling, Joseph M Gibbons, et al.
Emerging Infectious Diseases|May 21, 2015
Consensus on the development of vaccines against naturally acquired melioidosisDirek Limmathurotsakul, Simon G P Funnell, Alfredo G Torres, et al.
The Lancet. Infectious Diseases|June 1, 2015
Design, recruitment, and microbiological considerations in human challenge studiesThomas C Darton, Christoph J Blohmke, Vasee S Moorthy, et al.
Pageof 13